2005 |
Nelarabine |
T-cell leukemia/lymphoma |
P9673 |
2006 |
PEG asparaginase |
Acute lymphoblastic leukemia |
1962 |
2011 |
Erwinia asparaginase |
Acute lymphoblastic
leukemia |
AALL07P2 |
2011
2013
|
Imatinib
|
Ph+ chronic myelogenous leukemia
Ph+ acute lymphoblastic leukemia
|
AAML0123
AALL0031
|
2015 |
Dinutuximab |
Neuroblastoma |
ANBL0032 |
2017 |
Pembrolizumab |
Hodgkin
lymphoma, MSI-H, TMB-H |
ADVL1621 |
2018 |
SC-PEG asparaginase |
Acute lymphoblastic
leukemia |
AALL07P4 |
2018 |
Blinatumomab |
Acute lymphoblastic leukemia |
AALL1121 |
2019 |
Dasatinib |
Ph+ acute
lymphoblastic leukemia |
AALL1122 |
2020 |
Gemtuzumab ozogamicin |
Acute myelogenous leukemia |
AAML0531 |
2021 |
Liposomal daunorubicin/cytarabine |
Acute
myelogenous leukemia |
AAML1421 |
2021 |
Recombinant Erwinia asparaginase |
Acute lymphoblastic leukemia |
AALL1931 |
2021 |
Rituximab |
CD20+ non-Hodgkin lymphoma |
ANHL1131 |
2021
2022
|
Crizotinib
|
Anaplastic large cell lymphoma,
Inflammatory myofibroblastic tumor
|
ADVL0912
|
2022 |
Brentuximab |
Hodgkin lymphoma |
AHOD1331 |